Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 3254: NIH IMPROVE Act”

Read twice and referred to the Committee on the Judiciary.

Original title: “S 4879: Let Doctors Provide Reproductive Health Care Act”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 4843: Enhancing Mental Health and Suicide Prevention Through Campus Planning Act”

EMA and the European Innovation Council and SMEs Executive Agency (EISMEA) have strengthened their cooperation in support of health innovation in the European Union (EU). Today…, Enabling innovation is central to our public health mission to bring new treatments to patients. Our collaboration with EISMEA helps us better support innovators to…, The earlier health innovators can engage with regulatory expertise, the better equipped they are to make informed development decisions, r

Original title: “EMA and EISMEA boost cooperation to accelerate health innovations”

The National Institute of Dental and Craniofacial Research (NIDCR) is developing its Strategic Plan for Fiscal Years 2027-2031. NIH is publishing this Request for Information (RFI) to solicit input from researchers in academia and industry; health care professionals; patient advocates and advocacy organizations; scientific and professional societies; federal partners; and other interested members of the public on topics under consideration for the next strategic plan. Organizations are strongly

Original title: “Request for Information (RFI): Inviting Comments and Suggestions on Topic Areas for the NIDCR Strategic Plan for Fiscal Years 2027-2031”

The Office of Refugee Resettlement is requesting a 3-year extension with revisions of the Unaccompanied Refugee Minors (URM) Program Application and Withdrawal of URM Program Application or Declination of URM Program Placement Forms (Office of Management and Budget #: 0970-0550, expiration July 31, 2026). Revisions were made to reduce burden and streamline information collection.

Original title: “Submission for Office of Management and Budget Review; Office of Refugee Resettlement Unaccompanied Refugee Minors Program Application and Withdrawal of Unaccompanied Refugee Minors Program Application or Declination of Unaccompanied Refugee Minors Program Placement Forms”

Original title: “National Institute on Minority Health and Health Disparities; Notice of Partially Closed Meeting”

As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that an in-person meeting is scheduled to be held for the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). The meeting will be open to the public as well as streamed live on hhs.gov/live. A pre-registered public comment session will be held during the meeting. Pre-registration is required for members of the public who wish to present th

Original title: “Meetings of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria”

Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost versions of drugs on standard formularies.

Original title: “CVS Caremark reaches settlement with FTC over insulin suit”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 9656: To amend title XI of the Social Security Act to require hospitals participating in Federal health care programs to report certain information related to immigration status.”

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 9645: Health Care Price Certainty for All Americans Act”

Referred to the House Committee on Veterans' Affairs.

Original title: “HR 9652: To authorize the Secretary of Veterans Affairs to carry out a minor medical facility project in Saipan, Commonwealth of the Northern Mariana Islands.”

Through the proposal, the FDA could clear barriers to distributed manufacturing approaches intended to enhance emergency preparedness and supply chain resilience.

Original title: “FDA proposes streamlined requirements for ‘hub-and-spoke’ manufacturing models”

Read twice and referred to the Committee on Finance. (text: CR S1616)

Original title: “S 4202: Mental Health Access and Provider Support Act of 2026”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 4878: Reproductive Health Care Training Act of 2026”

On April 18, 2026, President Trump issued Executive Order (E.O.) 14401, "Accelerating Medical Treatments for Serious Mental Illness", acknowledging that individuals suffering from serious mental illness may not always respond to existing therapies. This request for information (RFI) solicits stakeholder feedback on training and care delivery models that could be used to ensure safe and effective delivery of potential future Food and Drug Administration (FDA)- approved psychedelic drugs, includin

Original title: “Request for Information, Training and Care Delivery Models for Safe Administration of Potential FDA-Approved Psychedelic Therapies in Ambulatory Clinical Settings”

The Medicines and Healthcare Products ... for therapies to gain approval. The new guidance is built to overcome the challenges facing very rare diseases — specifically, the small patient numbers. Ultra-rare diseases are defined as those that affect fewer than 1 in 50,000 people, which makes recruiting the large cohorts required by conventional pathways not only slow but also difficult and expensive. The proposed framework will allow developers flexibility around how they conduct clinical trials, enable ... The Medicines and Healthcare Products Regulatory Agency (MHRA) unveiled the Rare Disease Therapies Regulatory Framework, designed to allow flexibility in how evidence is collected and presented to regulators to make it quicker and easier for therapies to gain approval. The new guidance is built to overcome the challenges facing very rare diseases — specifically, the small patient numbers. Ultra-rare diseases are defined as those that affect fewer than 1 in 50,000 people, which makes recruiting the large cohorts required by conventional pathways not only slow but also difficult and expensive. The proposed framework will allow developers flexibility around how they conduct clinical trials, enable changes in how they collect and present the evidence, and make it easier to incorporate surrogate and patient end-points as well as computational modelling, digital twins and non-animal methods. Nature Biotechnology - MHRA’s radical rare disease proposal

Original title: “MHRA’s radical rare disease proposal | Nature Biotechnology”

The Office of Refugee Resettlement (ORR) announces a change to the eligibility period for Refugee Cash Assistance (RCA) and Refugee Medical Assistance (RMA). Pursuant to ORR regulations at 45 CFR 400.211(b), the ORR Director (hereinafter "the Director") has determined that the RCA and RMA eligibility period will be increased from 4 months to 8 months. This change is intended to support the effective resettlement of refugees and other ORR-eligible populations and assist them in achieving economic

Original title: “Federal Register Notice: Change in Eligibility Period for Refugee Cash Assistance and Refugee Medical Assistance”

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Psychedelic Drugs: Considerations for Clinical Investigations." Because interest in the therapeutic potential of psychedelic drugs has been increasing and designing clinical trials to evaluate these compounds presents unique challenges, FDA developed the draft guidance to present foundational aspects for sponsors to consider. This final guidance provides general considerations

Original title: “Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability”